Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

黄色ブドウ球菌は人間の皮膚に一般的に見られますが、機会主義的な病原体です。メチシリン耐性黄色 ブドウ球菌( MRSA)は、メチシリンやペニシリンなどほとんどのβラクタム系抗生物質に耐性を持つ黄色 球菌 の一種です。MRSA株は、ほとんどのβ-ラクタムが標的とするペニシリン結合タンパク質(PBP)を変化させます。MRSA株では、この耐性はmecA遺伝子の存在によって発生します。 mecA 遺伝子はPBP2aと呼ばれるペニシリン結合タンパク質をコードしています。この変異PBP2aはβ-ラクタム抗生物質に対する結合親和性が低いため、これらの薬剤の存在下でもMRSAは細胞壁を合成できます。多くのMRSA株では、mecA発現を制御する調節遺伝子mecIおよびmecR1は機能しません。これによりPBP2aの持続的な発現と安定した耐性の発達が促されます。MRSAは、細菌集団の一部だけが耐性を示す異質耐性、または集団全体が耐性を持つ均質耐性を示すことがあります。

mrsaにおける抗生物質耐性のメカニズム

Mechanism of Antibiotic Resistance in MRSA

細菌の抗生物質耐性は、微生物が殺す薬や増殖を抑制する薬に耐える能力を進化させ、かつて効果的だった治療が無意味になることで生じます。この現象は、遺伝的変化や抗生物質曝露下の選択によって引き起こされ、現代医学にとって深刻な脅威となっています。メカニズムには、薬物不活性化酵素(例:β-ラクタマーゼ)、抗生物質を排出する排出ポンプ、抗生物質標的を変える変異、薬物の吸収減少、そして水平遺伝子移動による耐性遺伝子の獲得が含まれます。耐性は突然変異を通じて新たに発達する場合もあれば、プラスミドやトランスポゾンのような移動性遺伝要素を通じて急速に広がることもあります。抗生物質の誤用や過剰使用による選択圧は耐性株の出現と拡散を加速させます。臨床的には、抗生物質耐性感染症は治療が難しく、より毒性が強い薬や高価な薬が必要になることが多いです。入院期間が長くなり、医療費が上昇し、罹患率や死亡率が増加します。世界的な推計では、抵抗傾向が続けば毎年数百万人の死亡が予想されています。メチシリン耐性黄色ブドウ球菌(MRSA) MRSAは抗生物質耐性の典型例です。SCCmec要素を通じてmecA遺伝子を獲得し、S. aureusは変異したペニシリン結合タンパク質PBP2aを産生しますが、これはβ-ラクタム薬剤に結合せず、ペニシリン、セファロスポリン、カルバペネムに対する広範な耐性をもたらします。MRSAは病院(HA-MRSA)で発生し、その後コミュニティ(CA-MRSA)で、変異と水平遺伝子移動の両方によって駆動されました。臨床的には、MRSAは重度の皮膚、軟部組織、血流、肺炎感染症を引き起こし、バンコマイシン、ダプトマイシン、リネゾリドで治療されることが多いですが、これらの代替手段には限界があります。細菌における抗生物質耐性の他の例:バンコマイシン耐性腸球菌(VRE)とVRSA バンコマイシンに耐性を持つ腸球菌は、van遺伝子オペロン(例:vanA)の獲得を通じて出現しました。これらの遺伝子はさらにS. aureusに移行し、希少だが危険なバンコマイシン耐性 S. aureus (VRSA)株が生まれました。VRSA感染症は代替手段が限られているため治療が困難であり、稀であるにもかかわらず臨床的に深刻な懸念事項となっています。薬剤耐性 肺炎連鎖球 菌(DRSP) 肺炎球菌 は、ペニシリン結合タンパク質の変異を通じてペニシリンに対する耐性を、メチルトランスフェラーゼ遺伝子を介してマクロリドに対して耐性を発達させています。これらの変更により肺炎、髄膜炎、中耳炎の治療効果が低下し、セファロスポリンやフルオロキノロンなどのリスクを伴う上位抗生物質が必要となりました。まとめると、抗生物質耐性は遺伝的適応と遺伝子交換を通じて進化し、MRSA、VRE/VRSA、DRSPなどの主要な病原体に対して顕著な臨床的影響を示します。適切な抗生物質使用の確保、耐性パターンの監視、感染制御、新規治療薬の開発は、この増大する公衆衛生危機を緩和するために依然として不可欠です。

MRSAにおける抗生物質耐性のメカニズム

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, ...

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

JoVE Core

Microbiology

微生物学

Unit

ユニット

Antimicrobial Agents

抗微生物剤

KEY TERMS AND CONCEPTS

主要な用語と概念

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags